ER-positive/HER2-negative and ER-negative/HER2-negative breast cancer biopsies (USO-02103 cohort)
Summary:
Analysis of pre-treatment biopsies from 62 HER2-normal breast cancer patients (ER-positive and ER-negative subtypes) from US Oncology clinical trial 02103. Results provide insight into molecular mechanisms associated with chemotherapy sensitivity in breast cancer subtypes.
GPL96:
[HG-U133A] Affymetrix Human Genome U133A Array
Citation:
Iwamoto T, Bianchini G, Booser D, Qi Y et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst 2011 Feb 2;103(3):264-72. PMID: 21191116
